Apratastat
Alternative Names: TMI-005Latest Information Update: 10 Aug 2009
Price :
$50 *
At a glance
- Originator Amgen
- Developer Amgen; Wyeth
- Class Anti-inflammatories; Antirheumatics; Morpholines; Small molecules
- Mechanism of Action Matrix metalloproteinase inhibitors; Tumour necrosis factor-alpha convertase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 11 Jul 2005 Data presented at the Annual European Congress of Rheumatology (EULAR-2005) have been added to the adverse events and Rheumatoid Arthritis pharmacodynamics sectionS ,,
- 16 Nov 2004 Phase-II clinical trials in Rheumatoid arthritis in Canada (PO)
- 16 Nov 2004 Phase-II clinical trials in Rheumatoid arthritis in USA (PO)